Tempus AI (TEM) has been busy, with FDA approval for its xT CDx tumor-only sequencing platform, new hematologic cancer testing, and upgraded AI tools for clinicians and drug developers drawing fresh attention to the stock.

Despite a steady flow of new AI tools, clinical tests, and research initiatives in recent weeks, Tempus AI’s short term share price return has been weak. The stock closed at US$48.82, with the year to date share price return down 21.71%, while the 1 year total shareholder return is down 29.63%. This suggests that recent enthusiasm has not yet translated into sustained positive momentum.

If you are tracking how AI healthcare stories like Tempus play out, it can be useful to see what else is moving in the sector. A starting point is 39 healthcare AI stocks.

With Tempus reporting annual revenue of US$1,364.17m, a market cap around US$8.73b, and continued losses of US$302.91m, the key question is whether today’s weaker share price reflects undervaluation or whether markets are already pricing in future growth.

Most Popular Narrative: 27.4% Undervalued

Tempus AI’s most followed valuation story places fair value at $67.20 per share, well above the last close of $48.82. In that narrative, the stock is framed as discounted.

Significant volume growth and market share gains in both oncology and hereditary/genetic testing indicate that Tempus AI is leveraging its expanding data repository and technological differentiation to outperform competitors, positioning the company for durable top-line revenue growth.

Want to see what underpins that confidence in Tempus AI’s data engine? The valuation leans on faster revenue expansion, rising margins, and a richer earnings multiple. Curious how those levers combine to reach that fair value target? The full narrative lays out every step of the growth and profitability blueprint.

Result: Fair Value of $67.20 (UNDERVALUED)

However, that upside story can quickly weaken if competition squeezes pricing power or if reimbursement and regulatory decisions delay revenue from new assays and AI tools.

Another View: Pricing Power Cuts Both Ways

The narrative that Tempus AI is 27.4% undervalued leans on future earnings, yet today the stock trades on a P/S ratio of 6.4x compared with 3.8x for the wider US Life Sciences industry and 3.7x for peers, even though it is still loss making. That premium can signal confidence or simply raise the bar for what needs to go right, so which side of that trade are you really on?

On the other hand, the current 6.4x P/S sits below a fair ratio of 7.1x, suggesting the market price could move closer to that level if sentiment lines up with those fundamentals over time. For anyone weighing valuation risk against upside potential, the gap between 6.4x and 7.1x is the real battleground for this story, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between risk and reward, it helps to move quickly, review the underlying data, and decide where you stand. To see how the positives and negatives balance out, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Tempus AI has caught your eye, do not stop there. Broaden your watchlist with a few focused stock ideas that fit different investing angles.

• Target potential mispricings by reviewing 46 high quality undervalued stocks that combine stronger fundamentals with prices that may not fully reflect their underlying metrics.
• Prioritize resilience by checking 63 resilient stocks with low risk scores that show lower risk scores, which can help steady your portfolio when individual stories become more volatile.
• Get ahead of the crowd by researching the screener containing 21 high quality undiscovered gems before they gain wider attention and shift onto more investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.